MNKD Key Statistics, Chart & Performance
The current stock price of MNKD is 5.67 USD. In the past month the price increased by 1.43%. In the past year, price decreased by -12.5%.
MNKD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.18 | 403.83B | ||
| AMGN | AMGEN INC | 14.97 | 176.25B | ||
| GILD | GILEAD SCIENCES INC | 14.99 | 152.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.12 | 115.03B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.15 | 81.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.71 | 52.53B | ||
| INSM | INSMED INC | N/A | 37.12B | ||
| NTRA | NATERA INC | N/A | 31.62B | ||
| BIIB | BIOGEN INC | 10.51 | 25.82B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.46 | 20.98B | ||
| INCY | INCYTE CORP | 15.38 | 19.39B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About MNKD
Company Profile
MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. The company is headquartered in Danbury, Connecticut and currently employs 407 full-time employees. The company went IPO on 2004-07-28. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Company Info
MANNKIND CORP
1 Casper Street
Danbury CONNECTICUT 91362 US
CEO: Michael E. Castagna
Employees: 407
Phone: 18186615000
MANNKIND CORP / MNKD FAQ
What does MNKD do?
MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. The company is headquartered in Danbury, Connecticut and currently employs 407 full-time employees. The company went IPO on 2004-07-28. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Can you provide the latest stock price for MANNKIND CORP?
The current stock price of MNKD is 5.67 USD. The price increased by 0.18% in the last trading session.
What is the dividend status of MANNKIND CORP?
MNKD does not pay a dividend.
How is the ChartMill rating for MANNKIND CORP?
MNKD has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the analyst forecast for MNKD stock?
15 analysts have analysed MNKD and the average price target is 9.24 USD. This implies a price increase of 62.9% is expected in the next year compared to the current price of 5.67.
When does MANNKIND CORP (MNKD) report earnings?
MANNKIND CORP (MNKD) will report earnings on 2026-02-24, after the market close.
Can you provide the ownership details for MNKD stock?
You can find the ownership structure of MANNKIND CORP (MNKD) on the Ownership tab.
MNKD Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to MNKD. When comparing the yearly performance of all stocks, MNKD is a bad performer in the overall market: 71.98% of all stocks are doing better.
MNKD Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to MNKD. Both the profitability and the financial health of MNKD get a neutral evaluation. Nothing too spectacular is happening here.
MNKD Financial Highlights
Over the last trailing twelve months MNKD reported a non-GAAP Earnings per Share(EPS) of 0.14. The EPS increased by 174% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 9.16% | ||
| ROA | 5.81% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MNKD Forecast & Estimates
15 analysts have analysed MNKD and the average price target is 9.24 USD. This implies a price increase of 62.9% is expected in the next year compared to the current price of 5.67.
For the next year, analysts expect an EPS growth of -0.55% and a revenue growth 20.91% for MNKD